Fmr LLC Sells 1,046,775 Shares of Invivyd, Inc. (NASDAQ:IVVD)

Fmr LLC decreased its stake in shares of Invivyd, Inc. (NASDAQ:IVVD) by 12.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,320,982 shares of the company’s stock after selling 1,046,775 shares during the period. Fmr LLC owned about 6.13% of Invivyd worth $7,467,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Marshall Wace LLP raised its position in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after acquiring an additional 474,301 shares in the last quarter. Duquesne Family Office LLC bought a new position in Invivyd in the second quarter worth approximately $629,000. Renaissance Technologies LLC bought a new stake in Invivyd during the second quarter valued at about $421,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Invivyd during the 2nd quarter worth approximately $263,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Price Performance

IVVD opened at $0.58 on Friday. The business has a fifty day moving average price of $0.84 and a 200 day moving average price of $1.08. Invivyd, Inc. has a 12 month low of $0.57 and a 12 month high of $5.20. The stock has a market capitalization of $69.37 million, a price-to-earnings ratio of -0.30 and a beta of 0.53.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on IVVD. HC Wainwright cut their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research note on Thursday, November 21st. Finally, Morgan Stanley lowered their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Invivyd has an average rating of “Buy” and an average price target of $7.89.

Insider Buying and Selling at Invivyd

In other news, Director Terrance Mcguire sold 150,000 shares of Invivyd stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $0.61, for a total transaction of $91,500.00. Following the sale, the director now owns 4,538,079 shares in the company, valued at approximately $2,768,228.19. The trade was a 3.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 17.90% of the company’s stock.

Invivyd Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.